UNDERWRITER COMMON STOCK PURCHASE WARRANT BIOSIG TECHNOLOGIES, INC.BioSig Technologies, Inc. • July 6th, 2021 • Electromedical & electrotherapeutic apparatus
THIS UNDERWRITER COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, _____________ or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after the Issue Date set forth above and on or prior to 5:00 p.m. (New York City time) on July __, 2026 (the “Termination Date”), but not thereafter, to subscribe for and purchase from BioSig Technologies, Inc., a Delaware corporation (the “Company”), up to ______1 shares (as subject to adjustment hereunder, the “Warrant Shares”) of the Company’s common stock, par value $0.0001 per share (the “Common Stock”). The purchase price of one share of Common Stock under this Warrant shall be equal to the Exercise Price, as defined in Section 2(b). This Warrant is being issued pursuant to that certain underwriting agreement, dated as of July __, 2021, by and among the Company and Laidlaw & Company (UK) Ltd., as representative
2,500,000 Shares BIOSIG TECHNOLOGIES, INC. Common Stock UNDERWRITING AGREEMENTUnderwriting Agreement • July 6th, 2021 • BioSig Technologies, Inc. • Electromedical & electrotherapeutic apparatus • New York
BioSig Technologies, Inc., a Delaware corporation (the “Company”), subject to the terms and conditions herein, proposes to sell to the underwriters (the “Underwriters”) named in Schedule I attached to this agreement (this “Agreement”) 2,500,000 shares (the “Firm Shares”) of the Company’s common stock, par value $0.001 per share (the “Common Stock”). In addition, the Company proposes to grant to the Underwriters an option to purchase up to 375,000 additional shares of Common Stock on the terms set forth in Section 2 (the “Option Shares”). The Firm Shares and the Option Shares, if and to the extent such option is exercised, are hereinafter collectively called the “Shares.”
